HSBC Holdings
CLYM

HSBC Holdings’s Climb Bio CLYM Stock Holding History

HSBC Holdings’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,744
Closed -$99.2K – 3294
2025
Q4 		$99.2K Buy
24,744
+12,800
+107% +$30.7K ﹤0.01% 2791
2025
Q3 		$23.9K Sell
11,944
-1,352
-10% -$2.51K ﹤0.01% 2671
2025
Q2 		$16.2K Sell
13,296
-3,430
-21% -$4.27K ﹤0.01% 2987
2025
Q1 		$21.4K Sell
16,726
-22
-0.1% -$36 ﹤0.01% 2966
2024
Q4 		$30K Buy
+16,748
New +$60.6K ﹤0.01% 3037

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

HSBC Holdings's CLYM Position: Q1 2026 in Review

HSBC Holdings sold out of Climb Bio (CLYM) in Q1 2026, closing a stake of 24,744 shares — an estimated $99.2K sold.

HSBC Holdings first reported a position in CLYM in Q4 2024 and held it in 5 quarters. The position peaked at $99.2K in Q4 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • HSBC Holdings reported no remaining Climb Bio position as of Q1 2026 after selling out during the quarter.
  • HSBC Holdings sold 24,744 Climb Bio shares in Q1 2026, an estimated $99.2K.
  • HSBC Holdings first reported a position in Climb Bio in Q4 2024 and held it in 5 quarters.
  • HSBC Holdings's Climb Bio position peaked at $99.2K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.